A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Stable Atherosclerosis.

Trial Profile

A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Stable Atherosclerosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 May 2011

At a glance

  • Drugs Aspirin; Clopidogrel; Prasugrel
  • Indications Atherosclerosis; Coronary artery disease; Embolism and thrombosis
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 27 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top